Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: Results of a Russian study

Objective. To evaluate the effect of progestogel as monotherapy on quality of life and magnitude of pain syndrome in fibrocystic mastopathy (FMP). Subjects and methods. The time course of changes in its symptoms was estimated using the pain visual analogue scale (VAS), the SF-6 health survey questionnaire, and ultrasonography in 798 patients diagnosed with FMP. Results. The pain VAS scores were 5.7 (5.0; 7.0) at baseline and statistically significantly lower [(2.4 (1.0; 4.0)] and [1.0 (0.0; 2.0)] after 3 and 6 months, respectively (p<0.05). The rate of diffuse and nodular changes was decreased by 44.3 and 60.4%, respectively. That of cystic masses ≥10 mm or less was reduced by 61.8 and 4.3%, respectively. There were physical and emotional improvements. Conclusion. Three-month progestogel monotherapy for FMP contributes to a decline in the number and extent of cystic changes, significantly reduces the magnitude of pain syndrome, and improves the quality of physical and mental health. © Bionika Media Ltd.